GSK
GSK earnings company data as of 4:45 AM ET 10/24
- 8 Owners
- Rank #150
- Max 3.5%
- Master 0.15%
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 28 Oct | EPS | 1.40 | — | — |
| Rev | — | — | — |
Who owns this now
Largest portfolio weights among holders, up to 3.5% (Hillman Capital Management). Not free-float ownership.
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 6-K | US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B | Filing Doc | |
| 6-K | JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER | Filing Doc | |
| 6-K | RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | WENDY BECKER CBE - NEW DIRECTORSHIP | Filing Doc | |
| 6-K | ADMISSION TO TRADING | Filing Doc | |
| 6-K | TOTAL VOTING RIGHTS | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | Filing Doc | ||
| 6-K | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA | Filing Doc | |
| 6-K | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA | Filing Doc | |
| 6-K | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 424B2 | Filing Doc | ||
| 6-K | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | Filing Doc | |
| 424B2 | Filing Doc | ||
| 6-K | Filing Doc | ||
| 6-K | TOTAL VOTING RIGHTS | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.